all report title image
  • Published On : Feb 2022
  • Code : CMI4915
  • Industry : Pharmaceutical
  • Pages : 154
  • Formats :

Allergy immunotherapy is the only casual treatment to prevent allergy caused by food, grass pollen, dust, and bee venom among other causes.

Increasing cases of allergies is expected to witness significant growth of the market over the forecast period. For instance, according to the International Study of Asthma and Allergies in Childhood (ISAAC) 2016, around 22.1% children aged between 13 to 14 years are affected due to pollen allergy (hay fever) at global level.

Hence, increasing cases of allergies is expected to increase the demand of allergy immunotherapy.

The global allergy immunotherapy market is estimated to be valued at US$ 2,116.0  million in 2022 and expected to exhibit a CAGR of 9.3%  over the forecast period (2022-2030).

Figure 1. Global Allergy Immunotherapy Market Share (%) in Terms of Value, by Region, 2022

Allergy Immunotherapy  | Coherent Market Insights

The rising incidence and prevalence of allergic disorders is expected to aid in the growth of the global allergy immunotherapy market.

For instance, according to the Centers for Disease Control and Prevention, the U.S. recorded 19.2 million and 5.2 million cases of hay fever in adults aged 18 and over and children under age 18 years, respectively, in 2018.

Moreover, the changes in environmental conditions and increasing pollution are driving the global allergy immunotherapy market growth. For instance, according to the Asthma and Allergy Foundation of America (AAFA), about 23 million people in the U.S. have symptoms from ragweed pollen allergy. These symptoms can make life depressed for those with allergies, which can also cause asthma symptoms for allergic asthma people.

CMI table icon

Allergy Immunotherapy Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 2,116.0 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 9.3% 2030 Value Projection: US$ 4,312.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT)
  • By Allergy Type: Allergic Rhinitis, Allergic Asthma, Food Allergy, Venom Allergy, Others
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:

Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier

Growth Drivers:
  • Increasing approval of allergy immunotherapy by regulatory authority
  • Rising incidence and prevalence of allergic disorders
Restraints & Challenges:
  • Lack of awareness among patients

Figure 2. Global Allergy Immunotherapy Market Share (%), by Distribution Channel, 2022

Allergy Immunotherapy  | Coherent Market Insights

Global Allergy Immunotherapy Market: Restraint

The lack of awareness among patients about allergy immunotherapy is expected to restrain growth of the global allergy immunotherapy market. Additionally, side effects associated with allergic immunotherapy is another factor that is predicted to restrict the market growth.

Global Allergy Immunotherapy Market - Impact Analysis of COVID-19

The COVID-19 outbreak has adversely affected the allergy immunotherapy market. It has become difficult for the researchers to conduct researches during this COVID-19 pandemic. People with ragweed pollen allergy are getting confused with the COVID-19 symptoms as the symptoms associated with both conditions are similar. Thus, the overall market is estimated to observe an optimistic growth during the COVID-19 pandemic.

Key Players

Major players operating in the global allergy immunotherapy market include Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier.

Immunotherapy is a preventive treatment for allergic reaction to substance such as grass pollens, house dust mites, and bee venom.

Subcutaneous immunotherapy (SCIT) and Sublingual immunotherapy (SLIT) are the immunotherapies used for the treatment of allergic rhinitis, allergic asthma, food allergy, venom allergy, and other allergies.

Subcutaneous immunotherapy (SCIT) is the most commonly used and effective form allergy immunotherapy. 

Market Dynamics

The global allergy immunotherapy market is expected to witness significant growth over the forecast period, owing to increasing approval of allergy immunotherapy by regulatory authority.

For instance, in 2017, ALk, a pharmaceutical company focusing on prevention, treatment, and diagnosis of allergy, received the U.S. Food and Drug Administration Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet Acarizax.

Furthermore, the tablet is also approved in Europe for the indication of house dust mite (HDM) for adults 18 through 65 years of age under the brand name Acarizax.

Key features of the study:

  • This report provides an in-depth analysis of the global allergy immunotherapy market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global allergy immunotherapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global allergy immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global allergy immunotherapy market

Detailed Segmentation:

  • Global Allergy Immunotherapy Market, By Treatment Type:
    • Subcutaneous Immunotherapy (SCIT)
    • Sublingual Immunotherapy (SLIT)
  • Global Allergy Immunotherapy Market, By Allergy Type:
    • Allergic Rhinitis
    • Allergic Asthma
    • Food Allergy
    • Venom Allergy
    • Others
  • Global Allergy Immunotherapy Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Allergy Immunotherapy Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Stallergenes Greer*
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • ALK-Abello A/S
    • Allergy Therapeutics
    • Allergopharma
    • HAL Allergy Group
    • Aimmune Therapeutics
    • DBV Technologies
    • Leti Pharma
    • Jubilant HollisterStier

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global allergy immunotherapy market size is estimated to be valued at US$ 2,116.0 million in 2022 and expected to exhibit a CAGR of 9.3%  between 2022 and 2030.
Increasing approval of allergy immunotherapy by regulatory authority & rising incidence and prevalence of allergic disorders is expected to drive the market growth over the forecast period.
Subcutaneous immunotherapy segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering the market growth include lack of awareness among patients.
Major players operating in the market include Stallergenes Greer, ALK-Abello A/S, Allergy Therapeutics, Allergopharma, HAL Allergy Group, Aimmune Therapeutics, DBV Technologies, Leti Pharma, and Jubilant HollisterStier.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo